Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
Latus Bio, Inc. (Latus), a biotechnology company engineering scalable gene therapies for broader patient populations, today announced the closing of a $97 million Series A financing to support its innovative therapeutics pipeline. The financing includes a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund. Korea Development Bank and Helen’s Pink Sky Foundation participated as new investors.
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease
Latus Bio, Inc. (Latus), a company advancing scalable genetic medicines for broad patient populations, today announced it will present new data at the 29th annual American Society of Gene and Cell Therapy (ASGCT) meeting, taking place May 11-15, in Boston, MA. The Company also announced that its founder, Beverly Davidson, Ph.D., was awarded ASCGT's highest honor, the Outstanding Achievement Award.
Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announces clearance by the U.S. Food and Drug Administration (FDA) of the Company’s Investigational New Drug (IND) application for LTS-101 - a gene therapy candidate that’s intended to treat the CNS manifestations of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease. The FDA has also granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations for LTS-101.
Latus Bio Launches AI/ML Strategy to Transform AAV Gene Therapy, Adds Two Leading Experts in Peptide and Protein Modeling to Scientific Advisory Board
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning (AI/ML) strategy and the addition of two world-class scientific advisors: Pranam Chatterjee, PhD (University of Pennsylvania) and Philip M. Kim, PhD (University of Toronto). The company’s AI/ML strategic evolution positions Latus Bio at the forefront of AI-driven innovation in AAV capsid discovery and payload design.
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research manuscript in Nature Communications: “Optimized AAV capsids for basal ganglia diseases show robust potency and distribution.”
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, “AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant protein in NHPs and a mouse model of lysosomal storage disease.”
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug candidate at the 20th Annual CHDI Huntington’s Disease (HD) Therapeutics Conference in Palm Springs, California, which is being held from February 24-27, 2025.
Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing
Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing. The funding round is being led by 8VC and DCVC Bio. To date, Samsung Life Science Fund (created by Samsung C&T, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation), The Children’s Hospital of Philadelphia Foundation, Benjamin Franklin Technology Partners, Modi Ventures, and Gaingels have joined as syndicate partners.
